Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2000; 21(6): 467-476
DOI: 10.1055/s-2000-13190
DOI: 10.1055/s-2000-13190
Hereditary and Acquired Thrombophilia
Further Information
Publication History
Publication Date:
31 December 2000 (online)
ABSTRACT
During the past decade knowledge about the etiology of venous thromboembolism has increased tremendously. Inherited and acquired risk factors for venous thromboembolism are common in patients as well as in the general population. Whether the presence of most of these risk factors has consequences for the management of symptomatic and asymptomatic individuals is not fully clear at present. Therefore, while searching for new thrombophilic defects, it is crucial to determine the absolute risk for (recurrent) venous thromboembolism as well as other clinical manifestations in carriers. However, tentative guidelines for managing patients and their families are given in this review.
KEYWORD
Thrombophilia - venous thromboembolism - risk factors - etiology - epidemiology
REFERENCES
- 1 Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med . 1992; 232 155-160
- 2 Bloemenkamp K W, Rosendaal F R, Helmerhorst F M, Buller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet . 1995; 346 1593-1596
- 3 Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh . 1965; 13 516-530
- 4 Clouse L H, Comp P C. The regulation of hemostasis: The protein C system. N Engl J Med . 1986; 314 1298-1304
- 5 Dahlback B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A . 1993; 90 1004-1008
- 6 Bertina R M, Koeleman B P, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
- 7 Voorberg J, Roelse J, Koopman R. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet . 1994; 343 1535-1536
- 8 Koster T, Rosendaal F R, de Ronde H, Briet E, Vandenbroucke J P, Bertina R M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet . 1993; 342 1503-1506
- 9 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med . 1999; 130 643-650
- 10 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood . 1996; 88 3698-3703
- 11 Simioni P, Tormene D, Manfrin D. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol . 1998; 103 1045-1050
- 12 Kamphuisen P W, Houwing-Duistermaat J, Van Houwelingen C H, Eikenboom J CJ, Bertina R M, Rosendaal F R. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost . 1998; 79 323-327
- 13 Koster T, Blann A D, Briet E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet . 1995; 345 152-155
- 14 Kraaijenhagen R A, in `t Anker S P, Koopman M MW, Reitsma P H, Prins M H, Buller H R. High plasma concentration of factor VIIIc: a major risk factor for venous thromboembolism. Thromb Haemost . 2000; 83 5-9
- 15 Meijers J CM, Tekelenburg W, Bouma B N, Bertina R M, Rosendaal F R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med . 2000; 342 696-701
- 16 Falcon C R, Cattaneo M, Panzeri D, Martinelli I, Mannucci P M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb . 1994; 14 1080-1083
- 17 Fermo I, Vigano' D S, Paroni R. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med . 1995; 123 747-753
- 18
den Heijer M, Koster T, Blom H J.
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.
N Engl J Med .
1996;
334
759-762
MissingFormLabel
- 19 Simioni P, Prandoni P, Burlina A. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost . 1996; 76 883-886
- 20 Boey M L, Colaco C B, Gharavi A E, Elkon K B, Loizou S, Hughes G R. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) . 1983; 287 1021-1023
- 21 Long A A, Ginsberg J S, Brill-Edwards P. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross- sectional study. Thromb Haemost . 1991; 66 520-524
- 22 Ginsburg K S, Liang M H, Newcomer L. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med . 1992; 117 997-1002
- 23 Ginsberg J S, Wells P S, Brill-Edwards P. Antiphospholipid antibodies and venous thromboembolism. Blood . 1995; 86 3685-3691
- 24 Simioni P, Prandoni P, Zanon E. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost . 1996; 76 187-189
- 25 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med . 1998; 104 332-338
- 26 Anderson G P. Insights into heparin-induced thrombocytopenia. Br J Haematol . 1992; 80 504-508
- 27 Agnelli G. Venous thromboembolism and cancer: a two-way clinical association. Thromb Haemost . 1997; 78 117-120
- 28 Tait R C, Walker I D, Perry D J. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol . 1994; 87 106-112
- 29 Tait R C, Walker I D, Reitsma P H. Prevalence of protein C deficiency in the healthy population. Thromb Haemost . 1995; 73 87-93
- 30 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden. Lancet . 1995; 346 1133-1134
- 31 Rosendaal F R, Doggen C J, Zivelin A. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost . 1999; 79 706-708
- 32 Heijboer H, Brandjes D P, Buller H R, Sturk A, ten Cate W J. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med . 1990; 323 1512-1516
- 33 Koster T, Rosendaal F R, Briet E. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood . 1995; 85 2756-2761
- 34 Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med . 1994; 330 517-522
- 35 Simioni P, Sanson B J, Prandoni P. The incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost . 1999; 81 198-202
- 36 Middeldorp S, Henkens C MA, Koopman M MW. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med . 1998; 128 15-20
- 37 Ridker P M, Hennekens C H, Lindpaintner K, Stampfer M J, Eisenberg P R, Miletich J P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med . 1995; 332 912-917
- 38 Sanson B J, Simioni P, Prins M H, on behalf of the TACT-study group. The incidence of venous thromboembolism in asymptomatic carriers of a marker of thrombophilia. Blood . 1999; 94 3702-3706
- 39 Simioni P, Prandoni P, Girolami A. Low rate of venous thromboembolism in asymptomatic relatives of probands with factor V Leiden mutation. Ann Intern Med . 1999; 130 538
- 40 Middeldorp S, Meinardi J R, Koopman M MW. A prospective study on the incidence of clinically overt venous thromboembolism in asymptomatic carriers of the FV:Q506 mutation. Thromb Haemost . 1999; 82(Suppl) 418 Abstract
- 41 Middeldorp S, Meinardi J R, van Thienen V J. The incidence of venous thromboembolism in relatives of patients with the prothrombin 20210A mutation. Thromb Haemost . 1999; 82(Suppl) 277 Abstract
- 42 Vandenbroucke J P, Koster T, Briet E, Reitsma P H, Bertina R M, Rosendaal F R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet . 1994; 344 1453-1457
- 43 Anonymous. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet . 1995; 346 1575-1582
- 44 Anonymous. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet . 1995; 346 1582-1588
- 45 Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet . 1995; 346 1589-1593
- 46 Spitzer W O, Lewis M A, Heinemann L A, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ . 1996; 312 83-88
- 47 Herings R MC, Urquhart J, Leufkens H GM. Venous thromboembolism among new users of different oral contraceptives. Lancet . 1999; 354 127-128
- 48 Ridker P M, Miletich J P, Stampfer M J, Goldhaber S Z, Lindpaintner K, Hennekens C H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation . 1995; 92 2800-2802
- 49 Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost . 1996; 75 229-232
- 50 Simioni P, Prandoni P, Lensing A W. The risk of recurrent venous thromboembolism in patients with an Arg506/Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med . 1997; 336 399-403
- 51 Eichinger S, Pabinger I, Stümpflen A. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost . 1997; 77 624-628
- 52 Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost . 1999; 81 684-689
- 53 Eichinger S, Minar E, Hirschl M. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost . 1999; 81 14-17
- 54 De Stefano V, Leone G, Mastrangelo S. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost . 1994; 72 352-358
- 55 Sanson B J, Friederich P W, Simioni P. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost . 1996; 75 387-388
- 56 Rosove M H, Brewer P M. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med . 1992; 117 303-308
- 57 Derksen R H, de Groot G P, Kater L, Nieuwenhuis H K. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis . 1998; 52 689-692
- 58 Pineo G F, Brain M C, Gallus A S, Hirsh J, Hatton M W, Regoeczi E. Tumors, mucus production, and hypercoagulability. Ann N Y Acad Sci . 1974; 230 262-270
- 59 Ambrus J L, Ambrus C M, Mink I B, Pickren J W. Causes of death in cancer patients. J Med . 1975; 6 61-64
- 60 Nand S, Fisher S G, Salgia R, Fisher R I. Hemostatic abnormalities in untreated cancer: Incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol . 1987; 5 1998-2003
- 61 Warkentin T E. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost . 1999; 82 439-447
- 62 Triplett D A, Harris E N. Antiphospholipid antibodies and reproduction. Am J Reprod Immunol . 1989; 21 123-131
- 63 Preston F E, Rosendaal F R, Walker I D. Increased fetal loss in women with heritable thrombophilia. Lancet . 1996; 348 913-916
- 64 Meinardi J R, Middeldorp S, de Kam J P. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med . 1999; 130 736-739
- 65 Grandone E, Margaglione M, Colaizzo D. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost . 1997; 77 1052-1054
- 66 Gopel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth. Lancet . 1999; 353 1411-1412
- 67 Branson H E, Katz J, Marble R, Griffin J H. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet . 1983; 2 1165-1168
- 68 Mahasandana C, Suvatte V, Marlar R A, Manco-Johnson M J, Jacobson L J, Hathaway W E. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet . 1990; 335 61-62
- 69 Broekmans A W, Bertina R M, Loeliger E A, Hofmann V, Klingemann H G. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost . 1983; 49 251
- 70 Conard J, Horellou M H, van Dreden P. Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosis. Lancet . 1992; 339 743-744
- 71 Rosendaal F R, Siscovick D S, Schwartz S M, Psaty B M, Raghunathan T E, Vos H L. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood . 1997; 90 1747-1750
- 72 Rosendaal F R, Siscovick D S, Schwartz S M. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood . 1997; 89 2817-2821
- 73 Chowdhury V, Lane D A, Mille B. Homozygous antithrombin deficiency: Report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost . 1994; 72 198-202
- 74 Schulman S, Rhedin A S, Lindmarker P. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med . 1995; 332 1661-1665
- 75 Kearon C, Gent M, Hirsh J. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med . 1999; 340 901-907
- 76 Palareti G, Leali N, Coccheri S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet . 1996; 348 423-428
- 77 van der Meer J F, Rosendaal F R, Vandenbroucke J P, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost . 1996; 76 12-16
- 78 Clagett G P, Anderson Jr A F, Heit J, Levine M, Wheeler H B. Prevention of venous thromboembolism. Chest . 1995; 108 312S-334S
- 79 van den Belt G M A, Sanson B J, Simioni P. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med . 1997; 157 2227-2232
- 80 Chae C U, Ridker P M, Manson J E. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost . 1997; 78 770-780
- 81 Brandjes D P, Heijboer H, Buller H R, de Rijk M, Jagt H, ten Cate W J. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med . 1992; 327 1485-1489
- 82 Koopman M M, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med . 1996; 334 682-687
- 83 Enzenauer R J, Berenberg J L, Campbell J. Progressive warfarin anticoagulation in protein C deficiency: a therapeutic strategy. Am J Med . 1990; 88 697-698
- 84 Ginsberg J S, Hirsh J. Use of antithrombotic agents during pregnancy. Chest . 1995; 108 305S-311S
- 85 Sanson B J, Lensing A WA, Prins M H. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost . 1999; 81 668-672
- 86 Christen W G, Ajani U A, Glynn R J, Hennekens C H. Blood levels of homocysteine and increased risks of cardiovascular disease: causal of casual?. Arch Intern Med . 2000; 160 422-434
- 87
Welch G N, Loscalzo J.
Homocysteine and atherothrombosis.
N Engl J Med .
1998;
338
1042-1050
MissingFormLabel
- 88 Middeldorp S, Buller H R, Prins M H, Hirsh J. Approach to the thrombophilic patient. In: Colman RW, Hirsh J, Marder VJ, Clowes G, eds. Hemostasis and Thrombosis: Basic
Principles and Clinical Practice
4th ed. Philadelphia: Lippincott Williams & Wilkins 2000
MissingFormLabel
- 89 Gallus A S. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost . 1997; 78 126-132
- 90 Prandoni P. Antithrombic strategies in patients with cancer. Thromb Haemost . 1997; 78 141-144
- 91 Wilde M I, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs . 1997; 54 903-924
- 92 Vandenbroucke J P, Helmerhorst F M, Bloemenkamp K W, Rosendaal F R. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol . 1997; 177 887-891
- 93 Middeldorp S, Briet E, Conard J. Familial thrombophilia. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular Thrombosis: Thrombocardiology
and Thromboneurology
2nd ed. Philadelphia: Lippincott-Raven, 1998: 59-75
MissingFormLabel
- 94 Prins M H, Hettiarachchi R J, Lensing A W, Hirsh J. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see?. Thromb Haemost . 1997; 78 121-125
- 95 van den Belt G M A, Prins M H, Huisman M V, Hirsh J. Familial thrombophilia: a review analysis. Clin Appl Thromb Hemost . 1996; 2 227-236
- 96 Pabinger I, Kyrle P A, Heistinger M. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost . 1994; 71 441-445
- 97 Ridker P M, Glynn R J, Miletich J P, Goldhaber S Z, Stampfer M J, Hennekens C H. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med . 1997; 126 528-531
- 98 Friederich P W, Sanson B J, Simioni P. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med . 1996; 125 955-960